We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




A Novel Procedure Treats High-Risk Aortic Aneurysms

By HospiMedica International staff writers
Posted on 27 Jul 2009
A combined endovascular and surgical approach (CESA) for treating thoraco-abdominal aortic aneurysms is being used in high-risk patients who cannot undergo traditional surgery.

Researchers at the University of California, Los Angeles (UCLA; USA) have so far performed the CESA procedure on 31 patients, and have reported excellent results in the first 20 high-risk patients with complex aortic pathology treated with CESA, operated on between 1998 and 2008. More...
Ten of the patients had prior aortic grafting, one patient had a functional renal transplant, and all patients were considered high risk based on preoperative comorbidities. During the CESA procedure, the surgeon first makes an incision in the abdomen to access vital arteries stemming from the aorta. Then performs bypasses on them in order to reroute effectively the blood flow so that the flow originates from an area of the aorta not affected by the aneurysm. Prosthetic grafts are used to provide circulation to the bypassed arteries during this first part of the procedure; this allows for the eventual exclusion of the segment of the aorta affected by the aneurysm, through the placement of a tiny endovascular device during the second, minimally invasive stage of the CESA procedure. This second stage is often completed at a later date, allowing the body time to recover and adjust to the new blood-flow pattern. Working through a small incision in the groin, the surgeons thread the small, tube-like endograft through the femoral artery and guide it towards the aortic aneurysm. Once in place and released, the endograft acts much like a stent, relining the aortic artery wall, and becomes the new conduit for blood flow, closing off the aneurysm.

UCLA's 10-year experience with the CESA technique demonstrated that the procedure is safe and durable. There was no perioperative mortality, and the cumulative survival rate at two years was 76%, comparable to the results after traditional surgical repair in acceptable-risk patients. There were major complications in six patients, including respiratory failure, deterioration of kidney function, and minor heart attack, as well as paraplegia in one patient. One patient refused to complete the second stage and died five months later from a ruptured aneurysm. The study describing the technique and the 10-year cumulative results was published in the May 2009 issue of the Journal of Vascular Surgery.

"Due to the tricky position of some aortic aneurysms or the frailty of some patients, not everyone is a candidate for standard surgery to treat a dangerous aneurysm,” said CESA developer Professor William Quinones-Baldrich, M.D., a professor of vascular surgery at the David Geffen School of Medicine at UCLA. "The CESA technique avoids opening the chest, which is done during standard surgery. After the endograft is placed, the patients usually can go home two to three days later, compared with longer stays that generally accompany traditional surgery.”

An aortic aneurysm is a general term for any dilatation of the aorta, usually representing an underlying weakness in the vessel wall at that location. While the stretched vessel may occasionally cause discomfort, a greater concern is the risk of rupture, which causes severe pain, massive internal hemorrhage, and without prompt treatment, results in a quick death.

Related Links:

University of California, Los Angeles



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Pressure Guidewire
SavvyWire
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.